ENDPOINTS NEWS9m
Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors
Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...
STAT25m
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Merck says injectable Keytruda succeeded in late-stage trial
Merck (NYSE:MRK) announced Tuesday that a subcutaneously delivered version of its blockbuster cancer therapy pembrolizumab ...
MarketWatch33m
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Yahoo Finance45m
Toragen reports positive results from trial of TGN-S11 for HPV-related cancer
The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...